Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664056 | 0.97 | NPC1 (0.55) | NPC1RAB9ACHRNB2CHRNA4DRD2 | |
| SCHEMBL16664061 | 0.93 | CA1 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16664057 | 0.93 | CA1 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16663991 | 0.93 | CA1 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16664113 | 0.92 | NPC1 (0.59) | NPC1RAB9ACHRNB2CHRNA4DRD2 | |
| SCHEMBL20837701 | 0.91 | RAB9A (0.55) | NPC1RAB9ADRD2TBXA2RMEN1 | |
| SCHEMBL16663998 | 0.90 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16664060 | 0.87 | CA1 (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16663996 | 0.87 | CA1 (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16663995 | 0.87 | CA1 (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3059224-B1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA EIYO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-9714213-B2 | 4-aminomethylbenzoic acid derivative | TOA EIYO LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| US-9714213-B2 | 4-aminomethylbenzoic acid derivative | TOA EIYO LTD. (JP) | 2017-07-25 | — | — | US | disclosed |
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA EIYO LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA EIYO LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3059224-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | TOA Eiyo Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015056663-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | トーアエイヨー株式会社 | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264514-A1 | 4-AMINOMETHYLBENZOIC ACID DERIVATIVE | ALDH7A1, CYP2B6, CYP2A6 | NPC1 2584/4885RAB9A 1074/4885CHRNB2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.